-+ 0.00%
-+ 0.00%
-+ 0.00%

Dogwood Therapeutics Reaches 50% Enrollment in Phase 2b Halneuron Trial for Chemotherapy-Induced Neuropathic Pain

Reuters·02/02/2026 13:31:08

Please log in to view news